Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)

Show document
A+ | A- | | SLO | ENG

Title:	Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)
Authors:	ID Aymon, Romain (Author) ID Mongin, Denis (Author) ID Guemara, Romain (Author) ID Salis, Zubeyir (Author) ID Askling, Johan (Author) ID Choquette, Denis (Author) ID Codreanu, Catalin (Author) ID Di Giuseppe, Daniela (Author) ID Flouri, Irini (Author) ID Huschek, Doreen (Author) ID Rotar, Žiga (Author), et al.
Files:	PDF - Presentation file, download (318,67 KB) MD5: C255AE8A2F5D486FA74C04B61E9E023F URL - Source URL, visit https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43188
Language:	English
Typology:	1.01 - Original Scientific Article
Organization:	UKC LJ - Ljubljana University Medical Centre
Keywords:	adverse cardiovascular events, rheumatoid arthritis, patients, Janus kinase inhibitors, biologic disease-modifying antirheumatic drugs, "JAK-pot" study
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2025
Number of pages:	str. 1194-1204
Numbering:	Vol. 77, no. 9, [article no.] 43188
PID:	20.500.12556/DiRROS-27900
UDC:	616-002
ISSN on article:	2326-5191
DOI:	10.1002/art.43188
COBISS.SI-ID:	234984707
Note:
Publication date in DiRROS:	27.02.2026
Views:	198
Downloads:	131
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

License:	CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International

Link:	http://creativecommons.org/licenses/by-nc/4.0/
Description:	A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Language:	Slovenian
Title:	Objective: To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF-inhibitors (TNFi) or biologic Disease-Modifying Anti-Rheumatic Drugs with other modes of action (bDMARD-OMA) in a multi-country, real-world population. Methods: RA patients from 15 registries in the JAK-pot collaboration were included. MACE incidence was analysed using two approaches: a within-registry analysis aggregating country-specific estimates from registers with >25 incident MACE events through meta-analysis, and an individual-level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRR) of MACE between treatment groups, accounting for multiple treatment courses. Results: The study included 73'008 treatment courses (16'417 JAKi, 35'373 TNFi and 21'218 bDMARD-OMA) and 828 incident MACE among 51'233 patients. Median follow-up time was 1.3 years, with most of the follow-up concentrated in the first two years of
Keywords:	neželeni srčno-žilni dogodki, revmatoidni artritis, bolniki, zaviralci Janus kinaze, biološkimi antirevmatiki, študija "JAK-pot"

Back